It is also in agreement with previous studies reported by our group, in which the NK-1 receptor antagonists L-733,060/L-732,138 and the drug aprepitant exerted an antitumor action on glioma, neuroblastoma, melanoma, retinoblastoma, pancreas, larynx, gastric and colon carcinoma cell lines [9,10,15,16,17,18,19,20,24,28]. This evidence concerns the gene TACR1 and central nervous system cancer.